71P GemSarc: A predictive gene signature for gemcitabine efficacy in advanced soft-tissue sarcoma

Background: Liposarcoma (LPS) and leiomyosarcoma (LMS) are rare forms of soft tissue sarcoma characterized by an aggressive course and limited therapeutic alternatives at an advanced stage.Eribulin mesylate, a synthetic microtubule inhibitor with initial approval for metastatic breast cancer, has shown promise in improving survival in patients with Liposarcoma and Leiomyosarcoma .This study explores the clinical utility of Eribulin in improving overall survival, progression-free survival, and treatment response rates in patients with liposarcoma and leiomyosarcoma.Methods: We conducted a comprehensive search of PubMed, Scopus, Web of Science, Embase, and Cochrane from their inception to January 2025, focusing on randomized controlled trials (RCTs) and observational studies evaluating Eribulin for the treatment of Liposarcoma and Leiomyosarcoma.Meta-analyses were performed using a random-effects model, with adverse events reported as the number of events and total patients.This approach was critical for calculating odds ratios (ORs) and mean differences (MDs), along with their 95% confidence intervals (CIs).Results: Out of 1,363 studies initially screened, 14 studies met the inclusion criteria for our meta-analysis, comprising 1,844 adult patients.The overall gender distribution included 1,199 females (65%) and 645 males (35%).Eribulin demonstrates significant efficacy in improving survival outcomes, with an Overall Survival (OS) proportion of 0.70 (95% CI: 0.58e0.82,P < 0.0001) and a Progression-Free Survival (PFS) proportion of 0.74 (95% CI: 0.62e0.86,P < 0.0001).The Objective Response Rate (ORR) was 0.16 (95% CI: 0.06e0.26,P < 0.0001), and the safety profile showed adverse event rates of neutropenia at 0.63 (95% CI: 0.63e0.77,P < 0.0001), anemia at 0.42 (95% CI: 0.28e0.57,P < 0.0001), and fatigue at 0.36 (95% CI: 0.22-0.49,P < 0.0001), supporting its role as a valuable treatment for liposarcoma and leiomyosarcoma.Conclusions: Eribulin improves survival in liposarcoma and leiomyosarcoma with a manageable safety profile, highlighting its value as an effective treatment and the need for further research to optimize its clinical use.